БЛОГ

Dec 26, 2022

An Antibody Successfully Treats Over 70% of Multiple Myeloma Patients in Trial

Posted by in category: biotech/medical

Almost every patient who gets myeloma and is treated with a standard therapy also experiences relapse. But researchers have developed an antibody therapy that triggers the immune system to destroy these cancer cells. The bispecific antibody can bind to T cells and multiple myeloma cells at once, to kill the cancer. This immunotherapy, called talquetamab, was astonishingly effective, and worked in about 73 percent of patients who were treated with the drug in two clinical trials. The treatment even helped for a patient who had a cancer that resisted all therapies that have been approved for multiple myeloma.

Talquetamab takes advantage of a receptor on myeloma cells called GPRC5D, and CD3, a complex and co-receptor on the surface of T cells. Anti-CD3 antibodies have long been known to cause the activation of T cells. Mouse studies showed that talquetamab can recruit and activate CD3-positive T-cells, which inhibits the formation and growth of tumors.

Comments are closed.